Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.

Read More »

SpringWorks Sets Stage for $115 Million IPO

Four months after securing $125 million in funding, SpringWorks Therapeutics is eying another $115 million from a potential initial public offering.

Read More »

Novartis executive sold shares before drug data manipulation made public

An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of the company’s gene therapy Zolgensma had been manipulated.

Read More »

U.S. FDA proposes new health warnings on cigarette packs, advertisements

The FDA proposed new health warnings for cigarette packages and ads due to small size and lack of an image in current warnings.

Read More »

Watch 6 key issues this autumn

A look at potential new developments important to health communications and marketing.

Read More »

FDA Issues Draft Guidance for Fabry Disease Drugmakers

The U.S. FDA issued a new draft guidance for drugmakers aiming their resources at Fabry disease, a rare genetic disease.

Read More »

Lexicon Posts Positive 52-Week Pooled Zynquista Data in Type 1 Diabetes

Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.

Read More »

U.S. FDA Expands Regulatory Approvals for LEO Pharma’s Enstilar Foam and Taclonex Topical Suspension in Treatment of Plaque Psoriasis

LEO Pharma Inc announced the U.S. Food and Drug Administration expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. Additionally, the FDA approved Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension in the topical treatment of scalp and body plaque psoriasis in patients 12 years and older.

Read More »

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105

Eton Pharmaceuticals Inc. announced that Aucta Pharmaceuticals Inc.’s New Drug Application for ET-105, an innovative formulation of lamotrigine which Eton acquired the U.S. marketing rights to in June 2019, was accepted for review by the U.S. Food and Drug Administration.

Read More »

Trump firms up plan to import medicines

The Trump administration took a step toward allowing the importation of medicines from Canada, an action the president has advocated as a way to bring cheaper Rx drugs to Americans.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom